NASDAQ:XNCR - Xencor Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $42.54 +0.23 (+0.54 %) (As of 07/20/2018 02:07 PM ET)Previous Close$42.58Today's Range$42.54 - $43.3752-Week Range$18.97 - $43.39Volume7,859 shsAverage Volume328,320 shsMarket Capitalization$2.34 billionP/E Ratio-40.68Dividend YieldN/ABeta1.64 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company's product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inhibitor that has been completed Phase I clinical trial for asthma and allergic diseases. Its product candidates also comprise XmAb14045, a bispecific oncology candidate, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; XmAb13676 that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers MOR208, an antibody drug, that in Phase III clinical trial to treat non-Hodgkin lymphomas, as well as in Phase II clinical trial for chronic lymphocytic leukemia; and AMG424, a bispecific CD38 x CD3 preclinical candidate for various myeloma. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104, which are in preclinical Phase. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. to develop and commercialize bispecific and other Fc engineered antibody drug candidates using its proprietary XmAb technologies and drug candidates, as well as MorphoSys Ag to develop and commercialize bispecific antibody product candidates; license agreement with Amgen Inc. to develop and commercialize bispecific antibody product candidates; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. Xencor, Inc.was founded in 1997 and is headquartered in Monrovia, California. Receive XNCR News and Ratings via Email Sign-up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:XNCR CUSIPN/A Webwww.xencor.com Phone626-305-5900 Debt Debt-to-Equity RatioN/A Current Ratio6.41 Quick Ratio6.41 Price-To-Earnings Trailing P/E Ratio-40.68 Forward P/E Ratio-18.26 P/E GrowthN/A Sales & Book Value Annual Sales$35.71 million Price / Sales66.27 Cash FlowN/A Price / CashN/A Book Value$6.01 per share Price / Book7.08 Profitability EPS (Most Recent Fiscal Year)($1.05) Net Income$-48,920,000.00 Net Margins-137.35% Return on Equity-18.07% Return on Assets-14.04% Miscellaneous Employees114 Outstanding Shares55,630,000Market Cap$2,335.70 Xencor (NASDAQ:XNCR) Frequently Asked Questions What is Xencor's stock symbol? Xencor trades on the NASDAQ under the ticker symbol "XNCR." How were Xencor's earnings last quarter? Xencor Inc (NASDAQ:XNCR) released its earnings results on Monday, May, 7th. The biopharmaceutical company reported ($0.62) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.46) by $0.16. Xencor had a negative return on equity of 18.07% and a negative net margin of 137.35%. View Xencor's Earnings History. What price target have analysts set for XNCR? 7 brokers have issued 1 year price targets for Xencor's shares. Their forecasts range from $28.00 to $56.00. On average, they anticipate Xencor's share price to reach $38.4286 in the next year. This suggests that the stock has a possible downside of 10.0%. View Analyst Ratings for Xencor. What is the consensus analysts' recommendation for Xencor? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Xencor stock? Here are some recent quotes from research analysts about Xencor stock: 1. According to Zacks Investment Research, "Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. " (5/11/2018) 2. Cantor Fitzgerald analysts commented, "XmAb5871 likely the asset of greatest interest in 2018. The B cell-targeting MAb is being tested in patients with IgG4 related disease (IgG4-RD) and in patients with systemic lupus erythematosus (SLE) with Phase 3 testing for the former expected to start in 2Q18 and data from Phase 2 testing for the latter expected in 4Q18. Because the MAb modulates B cell activity but does not eliminate them, we believe the safety profile could be regarded to be superior as compared with other therapies, e.g., Rituxan." (3/29/2018) Who are some of Xencor's key competitors? Some companies that are related to Xencor include Beigene (BGNE), Sarepta Therapeutics (SRPT), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS), FibroGen (FGEN), Loxo Oncology (LOXO), United Therapeutics (UTHR), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Dr.Reddy's Laboratories (RDY) and Ligand Pharmaceuticals (LGND). Who are Xencor's key executives? Xencor's management team includes the folowing people: Dr. Bassil I. Dahiyat Ph.D., Co-Founder, Chief Exec. Officer, Pres and Director (Age 48)Mr. John J. Kuch, VP of Fin. & Sec. (Age 59)Dr. John R. Desjarlais Ph.D., Chief Scientific Officer and Sr. VP of Research (Age 54)Dr. Edgardo Baracchini Jr., Ph.D., M.B.A., Chief Bus. Officer (Age 59)Dr. Paul A. Foster M.D., F.A.H.A., Chief Medical Officer and Sr. VP (Age 64) Has Xencor been receiving favorable news coverage? Media headlines about XNCR stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Xencor earned a news sentiment score of 0.12 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 45.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. Who are Xencor's major shareholders? Xencor's stock is owned by a number of of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.39%), Sphinx Trading LP (0.05%), Amalgamated Bank (0.01%), Bank of Montreal Can (0.01%) and Thompson Investment Management Inc. (0.01%). Company insiders that own Xencor stock include Bassil I Dahiyat, Bruce L A Carter, Edgardo Baracchini Jr, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III and Paul A Foster. View Institutional Ownership Trends for Xencor. Which institutional investors are selling Xencor stock? XNCR stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. Company insiders that have sold Xencor company stock in the last year include Bassil I Dahiyat, Edgardo Baracchini Jr, John J Kuch, John S Stafford III and Paul A Foster. View Insider Buying and Selling for Xencor. Which institutional investors are buying Xencor stock? XNCR stock was purchased by a variety of institutional investors in the last quarter, including Sphinx Trading LP, Amalgamated Bank, Bank of Montreal Can and Thompson Investment Management Inc.. View Insider Buying and Selling for Xencor. How do I buy shares of Xencor? Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Xencor's stock price today? One share of XNCR stock can currently be purchased for approximately $42.71. How big of a company is Xencor? Xencor has a market capitalization of $2.34 billion and generates $35.71 million in revenue each year. The biopharmaceutical company earns $-48,920,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. Xencor employs 114 workers across the globe. How can I contact Xencor? Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at 626-305-5900 or via email at [email protected] MarketBeat Community Rating for Xencor (NASDAQ XNCR)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 281 (Vote Outperform)Underperform Votes: 162 (Vote Underperform)Total Votes: 443MarketBeat's community ratings are surveys of what our community members think about Xencor and other stocks. Vote "Outperform" if you believe XNCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XNCR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/20/2018 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?